Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis

Abia, Pablo Ladrón; Vicente, Carmen Alcalá; Delgado, Sara Martínez; Bastida, Guillermo

doi:10.1016/j.gastre.2020.07.004

Cited by 5 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous case report showed successful therapy of MS and UC with fingolimod. 14 Therapeutic agents targeting common immune pathways reduce immunosuppressant burden in patients with more than 1 IMID.…”

Section: Discussionmentioning

confidence: 99%

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone

2023

View full text Add to dashboard Cite

Simultaneous occurrence of multiple sclerosis (MS) and ulcerative colitis (UC) is seldom encountered by clinicians and poses unique challenges. The sphingosine-1-phosphate receptor modulator ozanimod has been recently approved for UC. Ozanimod can be used in such scenarios where it can treat both conditions, reducing the need for multiple targeted therapies. We report the first case of successfully treated multiple sclerosis and UC with ozanimod.

show abstract

Section: Discussionmentioning

confidence: 99%

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone

2023

View full text Add to dashboard Cite

show abstract

“…The S1P inflammatory target is known in multiple sclerosis, where fingolimod, a non-selective S1P receptor agonist, has been used since 2010 [ 52 ]. In IBD, the experience regarding this medication dates back to 2018.…”

Section: Biologics and Small Moleculesmentioning

confidence: 99%

Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review

2023

View full text Add to dashboard Cite

Crohn’s disease (CD) and ulcerative colitis (UC), known as inflammatory bowel diseases (IBD), are characterized by chronic inflammation of the gastrointestinal tract. Over the last two decades, numerous medications have been developed and repurposed to induce and maintain remission in IBD patients. Despite the approval of multiple drugs, the major recurring issues continue to be primary non-response and secondary loss of response, as well as short- and long-term adverse events. Most clinical trials show percentages of response under 60%, possibly as a consequence of strict inclusion criteria and definitions of response. That is why these percentages appear to be more optimistic in real-life studies. A therapeutic ceiling has been used as a term to define this invisible bar that has not been crossed by any drug yet. This review highlights novel therapeutic target agents in phases II and III of development, such as sphingosine-1-phosphate receptor modulators, selective Janus kinase inhibitors, anti-interleukins, and other small molecules that are currently under research until 1 January 2023. Emerging treatments for CD and UC that have just received approval or are undergoing phase III clinical trials are also discussed in this review.

show abstract

“…These agents have shown their effectiveness in MS in different clinical trials compared to placebo, IFNγ or TFM ( Calabresi et al, 2014 ; Kappos et al, 2018 ; Comi et al, 2019 ; Kappos et al, 2021 ). Although there are preclinical and clinical studies using S1P modulators in IBD ( Danese et al, 2018 ; Ladrón Abia et al, 2021 ), FGM, PNE or SPM have not been investigated in clinical trials ( Longbrake and Racke, 2009 ).…”

Section: Treatment Of Anti-cd20-induced Colitis and De Novo...mentioning

confidence: 99%

“…Although there are preclinical and clinical studies using S1P modulators in IBD (Danese et al, 2018;Ladrón Abia et al, 2021), FGM, PNE or SPM have not been investigated in clinical trials (Longbrake and Racke, 2009). OZA is the first S1P-receptor modulator approved for the treatment of UC.…”

Section: Treatment Of Anti-cd20-induced Colitis and De Novo Ibd: Reco...mentioning

confidence: 99%

Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review

Quesada-Simó,

Garrido-Marín,

Nos

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Multiple sclerosis (MS) and inflammatory bowel disease (IBD) are autoimmune disorders characterized by inflammatory episodes affecting the brain and the gastrointestinal (GI) tract, respectively. The frequent association between MS and IBD suggests that both conditions may share common pathogenic mechanisms. However, different responses to biological therapies indicate differences in immune mechanisms of inflammation. Anti-CD20 therapies are high efficacy treatments increasingly used to control inflammatory bursts in MS, but they may alter GI homeostasis and promote the development of bowel inflammation in susceptible individuals. This review analyzes the mechanistic association between immunity in MS and IBD, the effect of anti-CD20 therapies on the gut microenvironment, and provides recommendations for early detection and management of GI toxicities in the context of B-cell depletion in MS patients.

show abstract

Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis

Cited by 5 publications

References 5 publications

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone

Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review

Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review

Contact Info

Product

Resources

About